EZETIMIBE

SynDRA canonical compound SYN0004010 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	NPC1L1
Mechanism of action	Niemann-Pick C1-like 1 protein antagonist
Indication	hypercholesterolemia \| hyperlipidemia \| hyperlipidemia, hypercholesterolemia, sitosterolemia \| sitosterolemia
Disease area	endocrinology \| endocrinology \| endocrinology, metabolism \| metabolism

All known targets

SCH58235
SCH-58235
ezetimib
ezedoc
ezentia
ezetrol
zetia
Ezetimiba
MK0653
NSC-758923
Ezetimibe component of k-924
Ezetimibe component of liptruzet
Ezetimibe component of nexlizet
Ezetimibe component of roszet
Ezetimibe component of vytorin
Ezetrol
Zetia
Ezedoc
Ezetimib
Zient
Essex brand of ezetimibe
MSD brand of ezetimibe
Merck brand of ezetimibe
Ezetimibe [USAN:INN]
Inegy (TN)
MK-0653
Schering-Plough brand of ezetimibe
Vytorin (TN)
Zetia (TN)
Zetia , Ezetrol, Ezetimibe
Ezetimibe (JAN/USAN/INN)
(-)-Sch 58235
(1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
ezetimibe (usp monograph)